ClinicalTrials.gg
Active, not recruitingNCT04936685Updated Aug 28, 2026Results posted

Study on an Investigational Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Administered as a 5- and/or 10-year Booster Doses in Children and Adolescents Vaccinated 5 or 10 Years Earlier as Toddlers

A Phase 3 interventional study of Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine in Meningococcal Immunisation and Healthy Volunteers, sponsored by Sanofi Pasteur, a Sanofi Company. Active, not recruiting at 27 sites in 4 countries. Open to participants aged 6 Years to 7 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-28.

Sponsored by Sanofi Pasteur, a Sanofi Company (part of Sanofi) · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
209
Allocation
Randomized
Ages
6 Years to 7 Years
Sex
All
01

Study summary

The purpose of the MEQ00073 study is to describe the immunogenicity and safety of a booster dose and persistence of a priming dose of MenACYW conjugate vaccine (MenQuadfi®) in adolescents who had been vaccinated approximately 10 years earlier as toddlers as part of the MET51 study and to describe the immunogenicity and safety of a second booster dose (as adolescents approximately 5 years after the first booster dose) and the persistence of a first booster dose of MenACYW in adolescents who had been primed with MenACYW conjugate vaccine as toddlers as part of the MET51 study and had received a first booster dose as children approximately 5 years after the priming dose.

Read the detailed description

The duration of each participant's participation will be approximately 5.5 years

02

Conditions studied

  • Meningococcal Immunisation
  • Healthy Volunteers
03

In context

Lead sponsor

Sanofi Pasteur, a Sanofi Company is the lead sponsor of 374 studies on the registry; 4 are open to participants now.

Of its 94 completed or terminated interventional studies of FDA-regulated products, 73 (78%) have results posted.

First submitted after Sanofi Pasteur became part of Sanofi.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 7 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Received MenACYW vaccine in MET51 study (Groups 1 and 3) and completed the study (attended Visit 2)
  • Participant and parent/ legally acceptable representative (LAR) are able to attend all scheduled visits and to comply with all trial procedures
  • Covered by health insurance, if required by local regulations

Exclusion criteria

Exclusion Criteria:

  • Known or suspected congenital or acquired immunodeficiency; or receipt of therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
  • History of meningococcal infection, confirmed either clinically, serologically, or microbiologically
  • At high risk for meningococcal infection during the trial (specifically but not limited to participants with persistent complement deficiency, with anatomic or functional asplenia, or participants traveling to countries with high endemic or epidemic disease)
  • Personal history of Guillain-Barré syndrome (GBS)
  • Personal history of an Arthus-like reaction after vaccination with a tetanus toxoid containing vaccine
  • Known systemic to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the trial or to a vaccine containing any of the same substances
  • Verbal report by parent or LAR of thrombocytopenia or suspected thrombocytopenia, contraindicating intramuscular (IM) vaccination
  • Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM vaccination
  • Previous vaccination against meningococcal disease with either the trial vaccine or another vaccine (ie, mono- or polyvalent, polysaccharide, or conjugate meningococcal vaccine containing serogroups A, C, W, or Y) with the exception of licensed MenC vaccination received during infancy (MET51 Group 3), of the single dose of meningococcal vaccine administered as part of study MET51 (Group 1 and 3) and of Meningococcal B vaccine
  • Receipt of any vaccine in the 4 weeks preceding the trial vaccination or planned receipt of any vaccine in the 4 weeks following trial vaccination except for influenza vaccination, which may be received at least 2 weeks before or after study vaccines. This exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines
  • Receipt of immune globulins, blood or blood-derived products in the past 3 months
  • Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first blood draw Participation at the time of study enrollment (or in the 4 weeks preceding the trial vaccination) or planned participation during the present trial period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion
  • Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature ≥ 38.0°C). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily
  • Identified as a natural or adopted child of the Investigator or employee with direct involvement in the proposed study
  • The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
209 participants (actual)

Study arms

  • Experimental
    Group 1

    Participants will receive a first booster dose of MenACYW conjugate vaccine at Day 1 and a second booster dose at year 5 of study MEQ00073

    Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

  • Experimental
    Group 2

    Participants will receive a single booster dose of MenACYW conjugate vaccine at year 5 of study MEQ00073

    Biological: Meningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

Interventions

  • BiologicalMeningococcal Polysaccharide (Serogroups A, C, W, and Y) Tetanus Toxoid Conjugate Vaccine

    Liquid solution for injection Intramuscular

    Also known as: MenACYW conjugate vaccine MenQuadfi®

06

What researchers measure

Primary outcomes

  1. Group 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse for serogroups A, C, W, and Y is defined as: percentage of participants with a pre-vaccination titer \< 1:8, who had achieved a post-vaccination titer \>= 1:16 or participants with a pre-vaccination titer \>= 1:8, who had achieved a post-vaccination titer at least 4-fold greater than the pre-vaccination titer. The seroresponse sufficiency was demonstrated if the lower limit of 1-sided 97.5% confidence interval (CI) is \> 75%.

    Time frame: Baseline (Day 1) and 30 days after the MenACYW conjugate vaccine 5-year booster dose

Secondary outcomes

  1. Antibody Persistence of Meningococcal (Groups 1 and 2): Percentage of Participants Achieving Titer (Seroprotection) >=1:8 hSBA and Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Titer >=1:8 Approximately 5 Years After the Primary Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as vaccine seroprotection. Seroprotection rate is defined as percentage of participants with hSBA titer and rSBA titer \>=1.8 who received MenACYW conjugate vaccine 5 years earlier. Antibody persistence of meningococcal serogroups A, C, W, and Y in children at 5 years (Groups 1 and 2).

    Time frame: At Day 1 (approximately 5 year after the administration of a priming dose as toddlers in study MET51)

  2. Group 1: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  3. Group 2: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  4. Group 1: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  5. Group 2: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  6. Group 1: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  7. Group 2: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  8. Group 1: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  9. Group 2: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  10. Group 1: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  11. Group 2: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

    Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  12. Group 1: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration

    Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  13. Group 2: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration

    Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  14. Group 1: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration

    Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.

    Time frame: Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose

  15. Group 2: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration

    Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.

    Time frame: From Baseline (Day 1) until end of the study (approximately 5.5 years)

  16. Group 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e.pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination).

    Time frame: Within 30 minutes after vaccination

  17. Group 1: Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

    All noxious and unintended responses to a study vaccine related to any dose was considered adverse reactions (AR). A solicited reaction is an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An injection/administration site reaction is an AR at and around the injection/administration site. Injection/administration site reactions are commonly inflammatory reactions. They were considered to be related to the study vaccine administered. Systemic reactions were all ARs that were not injection or administration site reactions and included systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination or administration site.

    Time frame: 7 days after vaccination

  18. Group 1: Number of Participants With Unsolicited AEs

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e. pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination). Unsolicited AEs included both serious and non-serious unsolicited AEs.

    Time frame: Within 30 days after vaccination

  19. Group 1: Number of Participants With Serious AEs (SAEs) and Adverse Event of Special Interest (AESI)

    A SAEs is defined as any untoward medical occurrence, at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other important medical event. An AESI (serious or non-serious) is defined as one of scientific and medical concern specific to the Sponsor's study vaccination or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

    Time frame: From the first study vaccine administration up to primary completion date of 09 March 2023, approximately 28 weeks

07

Results

Posted May 8, 2024

Participant flow

The study was conducted at 26 centers in 4 countries from 23 August 2022 to 06 February 2023.

Participant flow — Overall Study
MilestoneMenACYW: Group 1MenACYW: Group 2
Started93116
Completed92116
Not completed10
Withdrew: Protocol violation10

Outcome measures

PrimaryGroup 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse for serogroups A, C, W, and Y is defined as: percentage of participants with a pre-vaccination titer \< 1:8, who had achieved a post-vaccination titer \>= 1:16 or participants with a pre-vaccination titer \>= 1:8, who had achieved a post-vaccination titer at least 4-fold greater than the pre-vaccination titer. The seroresponse sufficiency was demonstrated if the lower limit of 1-sided 97.5% confidence interval (CI) is \> 75%.

Time frame:
Baseline (Day 1) and 30 days after the MenACYW conjugate vaccine 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With Sufficiency of Serum Bactericidal Assay Using Human Complement (hSBA) Vaccine Seroresponse at 30 Days Post Booster Dose
percentage of participantsMenACYW: Group 1
Serogroup A93.2 (85.7 to NA)
Serogroup C97.7 (92.0 to NA)
Serogroup W98.9 (93.8 to NA)
Serogroup Y98.9 (93.8 to NA)
SecondaryAntibody Persistence of Meningococcal (Groups 1 and 2): Percentage of Participants Achieving Titer (Seroprotection) >=1:8 hSBA and Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Titer >=1:8 Approximately 5 Years After the Primary Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as vaccine seroprotection. Seroprotection rate is defined as percentage of participants with hSBA titer and rSBA titer \>=1.8 who received MenACYW conjugate vaccine 5 years earlier. Antibody persistence of meningococcal serogroups A, C, W, and Y in children at 5 years (Groups 1 and 2).

Time frame:
At Day 1 (approximately 5 year after the administration of a priming dose as toddlers in study MET51)
Reported as:
Number · percentage of participants
Antibody Persistence of Meningococcal (Groups 1 and 2): Percentage of Participants Achieving Titer (Seroprotection) >=1:8 hSBA and Serum Bactericidal Assay Using Baby Rabbit Complement (rSBA) Titer >=1:8 Approximately 5 Years After the Primary Vaccination
percentage of participantsMenACYW: Group 1MenACYW: Group 2
hSBA titer >=1.8, Serogroup A78.3 (68.4 to 86.2)74.1 (65.2 to 81.8)
hSBA titer >=1.8, Serogroup C83.7 (74.5 to 90.6)86.2 (78.6 to 91.9)
hSBA titer >=1.8, Serogroup W84.8 (75.8 to 91.4)84.5 (76.6 to 90.5)
hSBA titer >=1.8, Serogroup Y71.7 (61.4 to 80.6)66.4 (57.0 to 74.9)
rSBA titer >=1.8, Serogroup A71.7 (61.4 to 80.6)61.7 (52.2 to 70.6)
rSBA titer >=1.8, Serogroup C59.8 (49.0 to 69.9)58.6 (49.1 to 67.7)
rSBA titer >=1.8, Serogroup W57.6 (46.9 to 67.9)58.0 (48.3 to 67.3)
rSBA titer >=1.8, Serogroup Y62.9 (52.0 to 72.9)60.6 (50.7 to 69.8)
SecondaryGroup 1: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Geometric mean · titer
Group 1: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y
titerMenACYW: Group 1
Day 1: hSBA, Serogroup A17.2 (12.6 to 23.3)
Day 31: hSBA, Serogroup A1143 (820 to 1594)
Day 1: hSBA, Serogroup C36.9 (25.7 to 52.9)
Day 31: hSBA, Serogroup C8933 (6252 to 12764)
Day 1: hSBA, Serogroup Y14.6 (10.8 to 19.7)
Day 31: hSBA, Serogroup Y3727 (2908 to 4776)
Day 1: hSBA, Serogroup W29.3 (21.7 to 39.7)
Day 31: hSBA, Serogroup W8656 (6393 to 11721)
Day 1: rSBA, Serogroup A150 (81.7 to 275)
Day 31: rSBA, Serogroup A8454 (6869 to 10405)
Day 1: rSBA, Serogroup C31.5 (18.8 to 52.8)
Day 31: rSBA, Serogroup C20427 (14379 to 29018)
Day 1: rSBA, Serogroup Y64.5 (35.0 to 119)
Day 31: rSBA, Serogroup Y7814 (6111 to 9991)
Day 1: rSBA, Serogroup W49.7 (26.6 to 93.0)
Day 31: rSBA, Serogroup W23354 (17251 to 31615)
SecondaryGroup 2: Geometric Mean Titers Against Meningococcal Serogroups A, C, W, and Y

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA and the rSBA and the results were expressed as geometric mean titers.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8
percentage of participantsMenACYW: Group 1
Day 1: hSBA >=1:4 titer, Serogroup A93.2 (85.7 to 97.5)
Day 31: hSBA >=1:4 titer, Serogroup A100 (95.9 to 100)
Day 1: hSBA >=1:8 titer, Serogroup A78.4 (68.4 to 86.5)
Day 31: hSBA >=1:8 titer, Serogroup A98.9 (93.8 to 100)
Day 1: hSBA >=1:4 titer, Serogroup C86.4 (77.4 to 92.8)
Day 31: hSBA >=1:4 titer, Serogroup C97.7 (92.0 to 99.7)
Day 1: hSBA >=1:8 titer, Serogroup C84.1 (74.8 to 91.0)
Day 31: hSBA >=1:8 titer, Serogroup C97.7 (92.0 to 99.7)
Day 1: hSBA >=1:4 titer, Serogroup Y78.4 (68.4 to 86.5)
Day 31: hSBA >=1:4 titer, Serogroup Y100 (95.9 to 100)
Day 1: hSBA >=1:8 titer, Serogroup Y73.9 (63.4 to 82.7)
Day 31: hSBA >=1:8 titer, Serogroup Y100 (95.9 to 100)
Day 1: hSBA >=1:4 titer, Serogroup W95.5 (88.8 to 98.7)
Day 31: hSBA >=1:4 titer, Serogroup W100 (95.9 to 100)
Day 1: hSBA >=1:8 titer, Serogroup W85.2 (76.1 to 91.9)
Day 31: hSBA >=1:8 titer, Serogroup W100 (95.9 to 100)
SecondaryGroup 2: Percentage of Participants With hSBA Titer >= 1:4 and >= 1:8

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128
percentage of participantsMenACYW: Group 1
Day 1: rSBA >=1:8 titer, Serogroup A72.7 (62.2 to 81.7)
Day 31: rSBA >=1:8 titer, Serogroup A100 (95.9 to 100)
Day 1: rSBA >=1:128 titer, Serogroup A64.8 (53.9 to 74.7)
Day 31: rSBA >=1:128 titer, Serogroup A100 (95.9 to 100)
Day 1: rSBA >=1:8 titer, Serogroup C62.5 (51.5 to 72.6)
Day 31: rSBA >=1:8 titer, Serogroup C98.9 (93.8 to 100)
Day 1: rSBA >=1:128 titer, Serogroup C37.5 (27.4 to 48.5)
Day 31: rSBA >=1:128 titer, Serogroup C98.9 (93.8 to 100)
Day 1: rSBA >=1:8 titer, Serogroup Y63.5 (52.4 to 73.7)
Day 31: rSBA >=1:8 titer, Serogroup Y98.9 (93.8 to 100)
Day 1: rSBA >=1:128 titer, Serogroup Y56.5 (45.3 to 67.2)
Day 31: rSBA >=1:128 titer, Serogroup Y98.9 (93.8 to 100)
Day 1: rSBA >=1:8 titer, Serogroup W58.0 (47.0 to 68.4)
Day 31: rSBA >=1:8 titer, Serogroup W98.9 (93.8 to 100)
Day 1: rSBA >=1:128 titer, Serogroup W50.0 (39.1 to 60.9)
Day 31: rSBA >=1:128 titer, Serogroup W98.9 (93.8 to 100)
SecondaryGroup 2: Percentage of Participants With rSBA Titer >= 1:8 and >= 1:128

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
percentage of participantsMenACYW: Group 1
Serogroup A93.2 (85.7 to 97.5)
Serogroup C97.7 (92.0 to 99.7)
Serogroup Y98.9 (93.8 to 100)
Serogroup W98.9 (93.8 to 100)
SecondaryGroup 2: Percentage of Participants With hSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the hSBA. hSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:16 for participants with pre-vaccination hSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination hSBA titer \>= 1:8.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination
percentage of participantsMenACYW: Group 1
Serogroup A89.8 (81.5 to 95.2)
Serogroup C96.6 (90.4 to 99.3)
Serogroup Y91.8 (83.8 to 96.6)
Serogroup W97.7 (92.0 to 99.7)
SecondaryGroup 2: Percentage of Participants With rSBA Titer >=4-Fold Rise From Pre-Vaccination to Post-Vaccination

Functional meningococcal antibody activity against serogroups A, C, Y, and W were measured in a serum bactericidal assay utilizing the rSBA. rSBA vaccine seroresponse is defined as a post-vaccination titer \>= 1:32 for participants with pre-vaccination rSBA titer \< 1:8, or a post-vaccination titer \>= 4-fold increase at post baseline for participants with pre-vaccination rSBA titer \>= 1:8.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration

Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Number · percentage of participants
Group 1: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration
percentage of participantsMenACYW: Group 1
Day 1: >= 0.01 IU/mL100 (95.9 to 100)
Day 31: >= 0.01 IU/mL100 (95.9 to 100)
Day 1: >= 0.1 IU/mL95.5 (88.8 to 98.7)
Day 31: >= 0.1 IU/mL100 (95.9 to 100)
SecondaryGroup 2: Percentage of Participants With >=0.01 International Units (IU)/mL and >=0.1 IU/mL Anti-Tetanus Antibody Concentration

Anti-tetanus antibodies were measured by diphtheria, tetanus, pertussis multiplexed electrochemiluminescent (DTP-ECL) assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous hemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human immunoglobulin (Ig)G conjugate.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration

Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.

Time frame:
Baseline (Day 1) and Day 31 after the administration of a 5-year booster dose
Reported as:
Geometric mean · IU/mL
Group 1: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration
IU/mLMenACYW: Group 1
Day 12.41 (1.77 to 3.30)
Day 3113.7 (12.0 to 15.7)
SecondaryGroup 2: Geometric Mean Concentrations of Anti-Tetanus Antibody Concentration

Anti-tetanus antibodies were measured by DTP-ECL assay, a multiplexed serological assay that allowed for the simultaneous quantification of human antibodies to 6 specific antigens including diphtheria toxoid, tetanus toxoid, and 4 pertussis antigens: pertussis toxin, filamentous haemagglutinin, fimbriae and pertactin. The captured antibodies were then detected using a sulfotag-conjugated anti-human Ig G conjugate.

Time frame:
From Baseline (Day 1) until end of the study (approximately 5.5 years)

Results for this outcome have not been posted.

SecondaryGroup 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e.pre-listed in the case report book (CRB) in terms of diagnosis and/or onset window post-vaccination).

Time frame:
Within 30 minutes after vaccination
Reported as:
Count of participants · Participants
Group 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)
ParticipantsMenACYW: Group 1
Group 1: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs)0
SecondaryGroup 1: Number of Participants With Solicited Injection Site Reactions and Systemic Reactions

All noxious and unintended responses to a study vaccine related to any dose was considered adverse reactions (AR). A solicited reaction is an "expected" AR (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRB. An injection/administration site reaction is an AR at and around the injection/administration site. Injection/administration site reactions are commonly inflammatory reactions. They were considered to be related to the study vaccine administered. Systemic reactions were all ARs that were not injection or administration site reactions and included systemic manifestations such as headache, fever, as well as localized or topical manifestations that are not associated with the vaccination or administration site.

Time frame:
7 days after vaccination
Reported as:
Count of participants · Participants
Group 1: Number of Participants With Solicited Injection Site Reactions and Systemic Reactions
ParticipantsMenACYW: Group 1
Solicited injection site reactions67
Solicited systemic reactions45
SecondaryGroup 1: Number of Participants With Unsolicited AEs

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study vaccine, whether or not considered related to the study vaccine. An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions (i.e. pre-listed in the CRB in terms of diagnosis and/or onset window post-vaccination). Unsolicited AEs included both serious and non-serious unsolicited AEs.

Time frame:
Within 30 days after vaccination
Reported as:
Count of participants · Participants
Group 1: Number of Participants With Unsolicited AEs
ParticipantsMenACYW: Group 1
Group 1: Number of Participants With Unsolicited AEs28
SecondaryGroup 1: Number of Participants With Serious AEs (SAEs) and Adverse Event of Special Interest (AESI)

A SAEs is defined as any untoward medical occurrence, at any dose that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, was a congenital anomaly/birth defect, or other important medical event. An AESI (serious or non-serious) is defined as one of scientific and medical concern specific to the Sponsor's study vaccination or program, for which ongoing monitoring and rapid communication by the Investigator to the Sponsor was appropriate.

Time frame:
From the first study vaccine administration up to primary completion date of 09 March 2023, approximately 28 weeks
Reported as:
Count of participants · Participants
Group 1: Number of Participants With Serious AEs (SAEs) and Adverse Event of Special Interest (AESI)
ParticipantsMenACYW: Group 1
SAE3
AESI0

Adverse events

Collected over From the first study vaccine administration up to primary completion date of 09 March 2023, approximately 28 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenACYW: Group 10/93 (0%)3/93 (3.2%)72/93 (77.4%)
MenACYW: Group 2———
Most frequent serious events
Most frequent serious events
EventMenACYW: Group 1MenACYW: Group 2
GastroenteritisInfections and infestations1/93—
GiardiasisInfections and infestations1/93—
Wrist FractureInjury, poisoning and procedural complications1/93—
Most frequent other events
Most frequent other events
EventMenACYW: Group 1MenACYW: Group 2
Injection Site PainGeneral disorders60/93—
Injection Site ErythemaGeneral disorders36/93—
MyalgiaMusculoskeletal and connective tissue disorders31/93—
Injection Site SwellingGeneral disorders28/93—
MalaiseGeneral disorders23/93—
HeadacheNervous system disorders20/93—
PyrexiaGeneral disorders14/93—

Baseline characteristics

Participants with data in Case report form (CRF) consisted of all study participants with CRF, i.e with data in the clinical database.

Age, Continuous
Age, Continuous(year)MenACYW: Group 1MenACYW: Group 2Total
Mean6.28 ± 0.5786.26 ± 0.4406.27 ± 0.505
Sex: Female, Male
Sex: Female, Male(Participants)MenACYW: Group 1MenACYW: Group 2Total
Female356095
Male5856114
Race (NIH/OMB)
Race (NIH/OMB)(Participants)MenACYW: Group 1MenACYW: Group 2Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White93113206
More than one race011
Unknown or Not Reported022
08

Study locations

27 sites
  • Investigational Site Number : 2460009
    Espoo, 02230, Finland
  • Investigational Site Number : 2460001
    Helsinki, 00100, Finland
  • Investigational Site Number : 2460006
    Helsinki, 00930, Finland
  • Investigational Site Number : 2460002
    Jarvenpaa, 04400, Finland
  • Investigational Site Number : 2460004
    Kokkola, 67100, Finland
  • Investigational Site Number : 2460007
    Oulu, 90220, Finland
  • Investigational Site Number : 2460003
    Pori, 28100, Finland
  • Investigational Site Number : 2460008
    Tampere, 33100, Finland
  • Investigational Site Number : 2460010
    Turku, 20520, Finland
  • Investigational Site Number : 2760011
    Bönnigheim, 74357, Germany
  • Investigational Site Number : 2760001
    Bramsche, 49565, Germany
  • Investigational Site Number : 2760007
    Bretten, 75015, Germany
  • Investigational Site Number : 2760004
    Erfurt, 99086, Germany
  • Investigational Site Number : 2760009
    Goch, 47574, Germany
  • Investigational Site Number : 2760015
    Hamburg, 22415, Germany
  • Investigational Site Number : 2760002
    Mönchengladbach, 41236, Germany
  • Investigational Site Number : 2760008
    Mönchengladbach, 41236, Germany
  • Investigational Site Number : 2760006
    Schönau am Königssee, 83471, Germany
  • Investigational Site Number : 2760003
    Tauberbischofsheim, 97941, Germany
  • Investigational Site Number : 3480002
    Budapest, 1042, Hungary
  • Investigational Site Number : 3480001
    Budapest, 1188, Hungary
  • Investigational Site Number : 3480005
    Miskolc, 3527, Hungary
  • Investigational Site Number : 3480006
    Székesfehérvár, 8000, Hungary
  • Investigational Site Number : 7240006
    Santiago de Compostela, Galicia [Galicia] 15706, Spain
  • Investigational Site Number : 7240001
    Madrid, Madrid, Comunidad de 28046, Spain
  • Investigational Site Number : 7240002
    Madrid, 28007, Spain
  • Investigational Site Number : 7240003
    Seville, 41014, Spain
09

References and documents

Publications

  • Martinon-Torres F, Simko R, Ebert R, Ramet M, Zocchetti C, Syrkina O, Bchir S, Bertrand-Gerentes I. Five-Year Immune Persistence of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) and Immunogenicity and Safety of a Booster Dose in Children. Infect Dis Ther. 2025 May;14(5):991-1010. doi: 10.1007/s40121-025-01121-6. Epub 2025 Apr 1. PubMed 40169489 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Mar 2023, 6 months.

Results were first posted in May 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2021
First posted
Jun 23, 2021
StartActual
Aug 23, 2022
Primary completionActual
Mar 9, 2023
CompletionEst.
Dec 26, 2027
Results first posted
May 8, 2024
Last update
Aug 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04936685
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Aug 23, 2022
Primary completion
Mar 9, 2023
Completion
Dec 26, 2027 (estimated)
Results posted
May 8, 2024
Last update
Aug 28, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion